Efficacy of Combined Suprachoroidal Stent and Cataract Surgery in Patients With Glaucoma.
Journal
Journal of glaucoma
ISSN: 1536-481X
Titre abrégé: J Glaucoma
Pays: United States
ID NLM: 9300903
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
28
5
2020
medline:
15
12
2020
entrez:
28
5
2020
Statut:
ppublish
Résumé
The purpose of this study was to evaluate the efficacy of intraocular pressure (IOP) control after combined CyPass Micro-Stent implantation and cataract surgery (combined surgery). All cases of combined surgery performed from February 2017 to July 2018 at Stein and Doheny Eye Institutes were reviewed. The primary outcome was a qualified success with stratified IOP targets based on criteria: final IOP (A) ≤18 mm Hg and reduction of 20%, (B) ≤15 mm Hg and reduction of 25%, (C) ≤12 mm Hg and reduction of 30%. Secondary outcome measures included postoperative IOP and number of medications, complications, additional glaucoma surgery, and postoperative refractive error. Predictive factors for failure were investigated. IOP spike was defined as a postoperative IOP ≥30 or >10 mm Hg increase from preoperative IOP. One hundred forty-one eyes (107 patients) were included. Mean (±SD) preoperative IOP was 15.4±3.4 mm Hg on an average of 2.2±1.1 medications. A statistically significant reduction in IOP and number of medications was seen at 12 months (13.8±4.2 mm Hg, 1.3±1.3 medications, P<0.001). Fifteen eyes (10.6%) had a postoperative IOP spike. Thirteen eyes (9.2%) experienced 17 complications (12.1%). Additional glaucoma surgery was performed in 3 eyes (2 patients). Cumulative success rates at 1 year based on criteria A, B, and C were 42%, 33%, and 28%, respectively. Lower preoperative IOP, greater preoperative medication number, the occurrence of postoperative IOP spike, and non-Caucasian ethnicity were associated with failure. Combined CyPass Micro-Stent implantation and cataract surgery may reduce glaucoma medication burden with a success rate of 28% to 42% at 1 year.
Identifiants
pubmed: 32459684
doi: 10.1097/IJG.0000000000001554
pii: 00061198-202008000-00004
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
627-638Références
Alcon Laboratories Inc. Instructions for use CyPass system Ref # CYP-241-S. 2016. Available at: www.accessdata.fda.gov/cdrh_docs/pdf15/p150037d. Accessed October 1, 2019.
Hoeh H, Ahmed II, Grisanti S, et al. Early postoperative safety and surgical outcomes after implantation of a suprachoroidal micro-stent for the treatment of open-angle glaucoma concomitant with cataract surgery. J Cataract Refract Surg. 2013;39:431–437.
Hoeh H, Vold SD, Ahmed IK, et al. Initial clinical experience with the CyPass Micro-Stent: safety and surgical outcomes of a novel supraciliary microstent. J Glaucoma. 2016;25:106–112.
Höh H, Grisanti S, Grisanti S, et al. Two-year clinical experience with the CyPass Micro-Stent: safety and surgical outcomes of a novel supraciliary micro-stent. Klin Monbl Augenheilkd. 2014;231:377–381.
Grisanti S, Margolina E, Hoeh H, et al. Supraciliary microstent for open-angle glaucoma: clinical results of a prospective multicenter study. Ophthalmologe. 2014;111:548–552.
Grisanti S, Grisanti S, Garcia-Feijoo J, et al. Supraciliary microstent implantation for open-angle glaucoma: multicentre 3-year outcomes. BMJ Open Ophthalmol. 2018;3:e000183.
Vold S, Ahmed II, Craven ER, et al. CyPass Study Group. Two-year COMPASS Trial results: supraciliary microstenting with phacoemulsification in patients with open-angle glaucoma and cataracts. Ophthalmology. 2016;123:2103–2112.
Alcon.com. CyPass recall information. 2018. Available at: www.alcon.com/cypass-recall-information. Accessed October 1, 2019.
García-Feijoo J, Rau M, Grisanti S, et al. Supraciliary Micro-stent Implantation for open-angle glaucoma failing topical therapy: 1-year results of a multicenter study. Am J Ophthalmol. 2015;159:1075–1081.
Garcìa-Feijoo J, Höh H, Uzunov R, et al. Supraciliary microstent in refractory open-angle glaucoma: two-year outcomes from the DUETTE Trial. J Ocul Pharmacol Ther. 2018;34:538–542.
Fili S, Seddig S, Papadopoulou E, et al. One-year results after Cypass implantation. Ophthalmologe. 2019;116:447–455.
Figus M, Posarelli C, Passani A, et al. The supraciliary space as a suitable pathway for glaucoma surgery: ho-hum or home run? Surv Ophthalmol. 2017;62:828–837.
Lavia C, Dallorto L, Maule M, et al. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: a systematic review and meta-analysis. PLoS One. 2017;12:e0183142.
Fontana H, Nouri-Mahdavi K, Caprioli J. Trabeculectomy with mitomycin C in pseudophakic patients with open-angle glaucoma: outcomes and risk factors for failure. Am J Ophthalmol. 2006;141:652–659.
Fontana H, Nouri-Mahdavi K, Lumba J, et al. Trabeculectomy with mitomycin C: outcomes and risk factors for failure in phakic open-angle glaucoma. Ophthalmology. 2006;113:930–936.
Shaarawy TM, Sherwood MB, Grehn F. World Glaucoma Association Guidelines on Design and Reporting of Glaucoma Surgical Trials. Amsterdam, The Netherlands: Kugler Publications; 2009.
Chen PP, Lin SC, Junk AK, et al. The effect of phacoemulsification on intraocular pressure in glaucoma patients. A report by the American Academy of Ophthalmology. Ophthalmology. 2015;122:1294–1307.
Schultz RO, Watzke RC, Sawyer TR. The long-term results from cyclodialysis. Arch of Ophthalmol. 1960;64:408–412.
Saheb H, Ianchulev T, Ahmed II. Optical coherence tomography of the suprachoroid after CyPass Micro-Stent implantation for the treatment of open-angle glaucoma. Br J Ophthalmol. 2014;98:19–23.
Kerr NM, Wang J, Perucho L, et al. The safety and efficacy of supraciliary stenting following failed glaucoma surgery. Am J Ophthalmol. 2018;190:191–196.